Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 23 04:00PM ET
25.14
Dollar change
+0.98
Percentage change
4.06
%
IndexRUT P/E- EPS (ttm)-2.90 Insider Own10.48% Shs Outstand79.28M Perf Week5.14%
Market Cap2.00B Forward P/E- EPS next Y-3.49 Insider Trans-3.87% Shs Float71.37M Perf Month6.08%
Income-212.22M PEG- EPS next Q-0.80 Inst Own98.64% Short Float13.98% Perf Quarter148.66%
Sales9.56M P/S209.64 EPS this Y-10.57% Inst Trans-0.74% Short Ratio8.37 Perf Half Y366.42%
Book/sh6.32 P/B3.98 EPS next Y-8.47% ROA-33.49% Short Interest9.98M Perf Year54.04%
Cash/sh7.47 P/C3.37 EPS next 5Y- ROE-39.34% 52W Range4.82 - 27.66 Perf YTD177.79%
Dividend Est.- P/FCF- EPS past 5Y-57.60% ROI-41.86% 52W High-9.11% Beta0.79
Dividend TTM- Quick Ratio7.58 Sales past 5Y148.90% Gross Margin55.49% 52W Low421.04% ATR (14)1.55
Dividend Ex-Date- Current Ratio7.58 EPS Y/Y TTM12.72% Oper. Margin-2464.41% RSI (14)59.02 Volatility6.41% 6.88%
Employees253 Debt/Eq0.02 Sales Y/Y TTM3.64% Profit Margin-2219.87% Recom1.00 Target Price43.86
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q9.77% Payout- Rel Volume0.72 Prev Close24.16
Sales Surprise-82.04% EPS Surprise-19.82% Sales Q/Q-20.80% EarningsFeb 28 AMC Avg Volume1.19M Price25.14
SMA202.05% SMA5019.52% SMA200120.34% Trades Volume858,965 Change4.06%
Date Action Analyst Rating Change Price Target Change
Mar-14-24Initiated Cantor Fitzgerald Overweight $60
May-22-23Upgrade Evercore ISI In-line → Outperform $20
Mar-31-23Downgrade Evercore ISI Outperform → In-line $20
Jul-20-22Initiated Chardan Capital Markets Buy $29
Jul-12-22Initiated Raymond James Strong Buy $29
Sep-07-21Initiated Evercore ISI Outperform $50
Jun-17-21Initiated Needham Buy $50
Apr-26-21Resumed Credit Suisse Outperform $37
Jul-07-20Initiated Wells Fargo Overweight $60
Jul-07-20Initiated Wells Fargo Overweight
Apr-22-24 04:05PM
Apr-04-24 01:30AM
Mar-27-24 09:00AM
Mar-21-24 04:05PM
Mar-15-24 07:01PM
04:02PM Loading…
Mar-04-24 04:02PM
07:00AM
Feb-29-24 12:00PM
07:00AM
Feb-28-24 05:20PM
04:40PM
04:05PM
Feb-27-24 09:00AM
Feb-26-24 06:55AM
Feb-21-24 04:05PM
09:00AM Loading…
Feb-20-24 09:00AM
Feb-15-24 05:00PM
Jan-29-24 08:54AM
Jan-22-24 04:05PM
Jan-05-24 08:30AM
Dec-21-23 04:05PM
Dec-13-23 08:30AM
Nov-29-23 09:03AM
Nov-28-23 10:09AM
10:02AM
07:01AM
06:30AM
Nov-21-23 04:05PM
09:00AM
Nov-08-23 06:12PM
04:05PM Loading…
04:05PM
Oct-23-23 04:05PM
Oct-07-23 07:30AM
Sep-26-23 09:00AM
Sep-25-23 09:00AM
Sep-21-23 04:05PM
Sep-11-23 07:28PM
Sep-07-23 09:00AM
Aug-31-23 09:00AM
Aug-30-23 09:00AM
Aug-21-23 04:05PM
Aug-15-23 09:00AM
Aug-08-23 07:15PM
04:05PM
Jul-21-23 04:05PM
Jul-12-23 07:24AM
Jun-21-23 04:05PM
Jun-20-23 09:00AM
Jun-08-23 09:00AM
May-22-23 04:05PM
May-17-23 12:38PM
07:00AM
May-09-23 06:15PM
04:05PM
May-04-23 09:00PM
Apr-28-23 10:08AM
Apr-27-23 03:40PM
Apr-24-23 09:00AM
Apr-21-23 04:05PM
Apr-17-23 09:00AM
Apr-13-23 09:00AM
Apr-11-23 11:23AM
Apr-05-23 10:14AM
Mar-31-23 11:44AM
Mar-30-23 04:16PM
03:25PM
07:00AM
Mar-25-23 10:17AM
Mar-21-23 04:05PM
Mar-13-23 09:00AM
Mar-01-23 04:05PM
Feb-28-23 07:45PM
04:05PM
09:00AM
Feb-27-23 04:40PM
08:00AM
Feb-23-23 08:00AM
Feb-21-23 08:29PM
Feb-14-23 09:00AM
Feb-07-23 09:00AM
Feb-02-23 05:17AM
Jan-20-23 05:12PM
Jan-18-23 09:00AM
Dec-23-22 06:48AM
Dec-15-22 07:37PM
07:00AM
Dec-14-22 07:22PM
04:10PM
01:44PM
12:10PM
08:09AM
07:00AM
Nov-18-22 09:35AM
Nov-11-22 05:50AM
Nov-08-22 06:25PM
04:05PM
Nov-01-22 09:00AM
Oct-16-22 09:53AM
Oct-11-22 04:05PM
Oct-06-22 09:00AM
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEVIN ARTHUR ADirectorApr 19 '24Option Exercise1.245,0006,20019,830Apr 22 05:28 PM
LEVIN ARTHUR ADirectorApr 19 '24Sale22.825,000114,12314,830Apr 22 05:28 PM
LEVIN ARTHUR ADirectorApr 03 '24Sale27.1120,000542,214253,872Apr 03 08:26 PM
Boyce SarahPresident and CEOApr 02 '24Option Exercise1.2428,00034,720140,117Apr 03 06:16 PM
Boyce SarahPresident and CEOApr 02 '24Sale26.2528,000734,919112,117Apr 03 06:16 PM
LEVIN ARTHUR ADirectorMar 19 '24Option Exercise1.245,0006,20019,830Mar 21 04:10 PM
LEVIN ARTHUR ADirectorMar 19 '24Sale23.975,000119,84814,830Mar 21 04:10 PM
MacLean Michael FChief Financial OfficerMar 13 '24Option Exercise8.8240,000352,80084,093Mar 15 04:12 PM
MacLean Michael FChief Financial OfficerMar 13 '24Sale24.5240,000980,76044,093Mar 15 04:12 PM
Boyce SarahPresident and CEOMar 12 '24Option Exercise1.2428,00034,720140,117Mar 12 05:29 PM
LEVIN ARTHUR ADirectorMar 12 '24Option Exercise1.2425,00031,00042,471Mar 12 08:41 PM
Boyce SarahPresident and CEOMar 12 '24Sale22.6328,000633,682112,117Mar 12 05:29 PM
LEVIN ARTHUR ADirectorMar 12 '24Sale22.0327,641609,01714,830Mar 12 08:41 PM
Boyce SarahPresident and CEOMar 08 '24Option Exercise1.2484,000104,160196,117Mar 12 05:29 PM
Boyce SarahPresident and CEOMar 08 '24Sale21.3984,0001,796,710112,117Mar 12 05:29 PM
Boyce SarahPresident and CEOMar 01 '24Option Exercise1.2484,000104,160196,117Mar 05 04:53 PM
Boyce SarahPresident and CEOMar 01 '24Sale20.1384,0001,691,306112,117Mar 05 04:53 PM
Boyce SarahPresident and CEOJan 22 '24Sale10.135,09251,58244,008Jan 23 03:13 PM
Flanagan W. MichaelCSTOJan 22 '24Sale10.134,12941,82735,871Jan 23 03:12 PM
McCarthy TeresaChief Human Resources OfficerJan 22 '24Sale10.132,06520,91817,035Jan 23 03:11 PM
LEVIN ARTHUR ADirectorJan 22 '24Sale10.131,85918,83217,471Jan 23 03:14 PM
MacLean Michael FChief Financial OfficerJan 22 '24Sale10.131,61616,37016,884Jan 23 03:11 PM